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1. Introduction
Tubal infertility and reproductive damage, preeclampsia and preterm births may potentially
occur in many of the 50 million women who are annually infected with Chlamydia trachoma‐
tis [reviewed in 1; 2- 4]. C.trachomatis infections of the genital tract are also reported to increase
the risk of human immunodeficiency virus type 1(HIV-1) susceptibility and viral shedding in
the genital tract either directly by pro-inflammatory signalling pathways or indirectly by their
effects on genital epithelial cells [5]. A dramatic increase in the number of HIV-1 chemokine
co-receptor CXCR4- and CCR5-positive T cell targets has also been reported in the endocervix
of C. trachomatis-positive women [6].
Gynecological cancer development is also suggested to be linked with Chlamydial genital tract
infections. Epidemiological reports have proposed that C.trachomatis may act as a co-factor in
the development of human papilloma virus (HPV)-induced squamous cell carcinomas (SCC),
with an association between distinct serovariants of C. trachomatis (B, D, E, G, I, and J) and SCC
being reported [7,8]. It is also likely that C. trachomatis co-infections of the lower genital tract
(LGT) play a role in carcinogenesis of the female upper genital tract (UGT), particularly
epithelial ovarian and type II carcinomas [9,10]. To explain the epidemiological associations
of Chlamydial infections cervical and ovarian cancer development it has been hypothesised
that the pathogen perhaps triggers epigenetic changes in host chromatin and impairs host
DNA repair pathways [11] or that it changes host cell survival pathways by disrupting DNA
damage signalling pathways associated with tumorigenesis [12].
The majority (70-80%) of genital tract infections in women are asymptomatic and are not
diagnosed or treated and persistent or “silent” infections are reported as occurring years after
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initial acquisition of Chlamydia with 50% of women continuing to shed the organism one year
after infection is diagnosed [13]. Left untreated the organisms can ascend to the uterus and
Fallopian tubes to cause pelvic inflammatory disease (PID). Inflammation of the Fallopian
tubes can lead to scarring and fibrosis which can then lead to ectopic pregnancy (EP), sub-
fertility and infertility with repeated or multiple infections increasing the chances of disease
sequelae [14-17]. Additionally, infections during pregnancy may result in peripartum trans‐
mission of Chlamydia to newborns potentially resulting in neonatal conjunctivitis and late-
onset pneumonia [18, 19].
Globally it is estimated that over 100 million adults were infected with C. trachomatis in 2008
[20]. The annual direct medical cost of sexually transmitted diseases (including Chlamydia and
those caused by HIV) has been estimated at $US16.9 billion [21]. Despite continued improve‐
ments in diagnostic and screening procedures for Chlamydia the incidence of infection contin‐
ues to increase with a significant increase, particularly in the rates of EP [22]. Even though
azithromycin is available to treat uncomplicated lower genital tract infections [23], antibiotic
therapy will not always be efficacious and one hypothesis is that Chlamydia treatments may in
fact attenuate protective immunity in some patients [24]. Recent evidence has shown that
although spontaneous resolution of infection before treatment occurred in 22% of naturally
infected women, following azithromycion treatment, 16.5% of women were re-infected and
this rate was higher (19.9%) in those women with persistent infection when compared with
the rate (5%) in women who spontaneously cleared the infection [25]. Repeat infections are
thought to be one of the primary causes of ongoing transmission of Chlamydia. Development
of a vaccine that can either prevent infection or disease is therefore of vital importance for
Chlamydia [26, 27].
1.1. The organism: C. trachomatis
Chlamydiae are small (0.5µm and genomes of 1.05Mb) gram negative intracellular bacteria and
the human pathobiotype, C. trachomatis comprises non-invasive biovars that infect squamo‐
columnar epithelial cells of the female genital tract [28-30]. C.trachomatis replicates within non-
acidic vacuoles of these genital tract cells, acquiring essential lipids from the host cell during
infection to survive and replicate [31]. Based on serologic differences elicited by variable
domain (VD) regions of the Chlamydial major outer membrane protein A (OmpA), C.tracho‐
matis biovars currently are classified into 19 serovars with serovars D-K causing urogenital
infections [32-37].
Urogenital isolates of C.trachomatis may also contain a highly conserved 7.5 kB non-integrative
plasmid that has a role in the pathobiology of these organisms [38, 39]. The plasmid functions
as a significant virulence factor in the murine model of genital tract disease [40] with plasmid
loss resulting in failure to induce upper genital tract pathology in this model [41]. Within
clinical isolates of C.trachomatis, carriage of the 7.5 kB plasmid is almost universal, although a
few naturally-occurring, plasmid deficient strains have been reported that are not associated
with increased disease severity [42-45]. Recently it was reported that naturally-occurring
plasmid-free urogenital isolates of C.trachomatis serovar F also had reduced infectivity and
virulence in a murine model [46].
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1.2. Developmental cycle
Chlamydia undergoes a unique biphasic developmental cycle that encompasses two forms of
reproduction; an intracellular phase of non-infectious metabolically active and replicative
forms of reticulate bodies (RBs) and the extracellular phase of infectious elementary bodies
(EBs) that attach to and invade epithelial cells [47; reviewed in 48, and 49 and 50].
Chlamydial infection of superficial columnar cervical cells in the FGT is initiated by the
attachment and endocytosis of the EB into these mucosal epithelial cells. EB containing
endosomes then are internalised within host-derived membranes where the pathogen then
hijacks both vesicular and non-vesicular mediated pathways of the host to obtain host-derived
membrane lipids, including sphingomyelin (SM) and cholesterol, for intracellular growth and
development [reviewed in 51]. Once resources such as sphingomyelin are obtained from the
host cell and the vesicle expands, the EBs differentiate into the metabolically active, non-
infectious and larger (0.8µm) reticulate bodies (RB) in the normal developmental cycle.
Transformation of the metabolically-inactive EBs into the metabolically-active RBs occurs at
approximately 3 h post-infection (pi), and replication by binary fission over a 24-48h time
period then is initiated [52]. The RB containing endosome expands and produces a micro‐
scopically-visible Chlamydial microcolony referred to as an “inclusion” [53]. RBs then use host
cell ATP and other metabolites to grow and replicate by binary fission within the Chlamydial
inclusion.
Many inducers of persistence (including Interferon gamma (IFN-g), amino acid starvation and
antibiotics) will result in deviation from the ‘normal developmental cycle’, resulting in a viable
but non-cultivable growth stage and the formation of large, abnormal developmental forms
termed aberrant bodies (ABs) also known as aberrant RB, or persistent bodies [54]. In normal
development, RBs will continue to divide undergoing between 8-12 rounds of replication.
Later in the infectious process, the RBs asynchronously begin to differentiate back into EBs,
there is evidence of intermediate bodies (IBs) at this stage and the EBs accumulate within the
inclusion. Depending upon the Chlamydial species, at 30-80h post-infection the infectious EB’s
that have matured from the RBs are released either by host cell lysis or by a packaged-release
mechanism called extrusion, allowing the EBs to infect neighbouring cells for successive
rounds of infection.
1.3. Intracellular survival strategies
C. trachomatis is proficient at maintaining enduring relationships with its host by modulating
and evading the immune system using a multitude of mechanisms [55]. These include
inhibiting IFN-g–inducible major histocompatibility complex (MHC) class II expression [56]
that in human endocervical cells is known to be mediated by direct and indirect (soluble)
factors [57]. The multiple potential mechanisms used by Chlamydia to dampen immune
responses recently have been summarized [58].
To modulate host signal transduction cascades and allow their developmental cycles to take
place Chlamydiae are known to secrete up to sixteen anti-host (effector) proteins (reviewed in
59; 60). They also recruit proteins from the host and the first identified host proteins to be
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recruited into the Chlamydial inclusion include the eukaryotic nuclear protein ZNF23, a pro-
apoptotic factor that potentially allows Chlamydia to inhibit host cell apoptosis thus enabling
bacterial survival in the host [61].
1.4. Chlamydial infections and disease sequelae
1.4.1. Infections in women
Significant reproductive morbidity can occur in women following infection of the LGT with
C. trachomatis. In the estimated 20% of women with symptoms, C.trachomatis infection of the
columnar epithelial cells of the endocervix can result in cervicitis [62-64; reviewed in 65] and
urethritis [66]. Severe complications of untreated LGT Chlamydial infections in women,
whether symptomatic or asymptomatic can result in ascension of the organism from the lower
to the UGT. Endometritis represents an early stage in the continuum from LGT infection
through to salpingitis, a Fallopian tube disease also confirmed to be associated with C.tracho‐
matis infection. Since a critical source of Fallopian tube inflammation is infection with
C.trachomatis, it has been hypothesized that C.trachomatis infection may be involved in chronic
tubal inflammation and subsequent fimbrial carcinogenesis and hence could perhaps be the
origin of some ovarian cancers [67]. Interestingly, a recent retrospective analysis of 34 cases of
serous pelvic carcinomas (which are the most frequent histologic type of ovarian cancers)
reported that 70% of cases did in fact involve the Fallopian tubes [68].
Chlamydial infection of the pelvis can lead to symptomatic pelvic inflammatory disease (PID)
that can result in Fallopian tube inflammation [69] and salpingitis is reported to occur in 20-40%
of women with untreated or repeated Chlamydial infections [70,71]. A recent model predicts
that annual screening would prevent 61% of C.trachomatis-related PID in women who became
infected in their LGTs with Chlamydia [72]. In addition to salpingitis the long-term consequen‐
ces of PID can also include chronic pelvic pain and ectopic pregnancy (EP). It has been
proposed that since C.trachomatis infection increases tubal expression of prokineticin receptor
(PROKR2) mRNA this expression then predisposes to ectopic implantation in the Fallopian
tube [73]. Recent papers have reported that one third of EPs could be attributable to Chlamydial
infection [74] and have also reviewed the pathogenesis of Chlamydia-induced tubal EP [75].
PID is caused by infection of the female genital tract with many microorganisms including C.
trachomatis [reviewed in 16] and following symptomatic PID of polymicrobial etiology up to
18% of women may develop tubal factor infertility (TFI), which is amongst the leading causes
of infertility accounting for 7-9.8% of all female factor infertilities [76-80]. Testing for serum
antibody to the Chlamydial 60kDa Heat shock protein (i.e.cHSP60 antibody) is an accurate
means for predicting Chlamydia-associated TFI [81] and elevated levels of anti-Chlamydial
caseinolytic protease P (ClpP) antibodies were recently identified in 21 TFI patients [82].
Prolonged exposure to Chlamydia due to a chronic persistent infection or frequent re-infection
has also been associated with chronic inflammation and TFI [83-85]. It has been reported that
9.5% women developed PID over 12 months in women who tested positive for Chlamydia at
baseline [86].
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1.4.2. Ophthalmia neonatorum and infant pneumonia
The high prevalence of Chlamydial infections of the cervix in women of child-bearing age
results in annual exposure of an estimated 100,000 neonates to Chlamydia infections [87] and
neonatal Chlamydial infections are generally acquired during passage through an infected
birth canal. A Chlamydial cause should be considered for all infants aged ≤30 days who have
conjunctivitis and, if positively diagnosed, appropriate treatment initiated for the infant,
mother and her sex partner(s).
Chlamydia infections of neonates have been reported to be at 18 percent for ophthalmia
neonatorum and 16 percent for pneumonia for infants exposed to C. trachomatis in vaginal
secretions in the birth canal, with up to 60% of these infants showing serological evidence of
Chlamydial infection [88]. Using data pooled from studies since 1977 it has been estimated
that the incidence of ophthalmia neonatorum caused by exposure of the neonate to C.tracho‐
matis at birth is actually around 15 percent and that of pneumonia is around 7 percent [89].
Neonatal infection with C. trachomatis involves the mucous membranes of the neonatal eye,
oropharynx, urogenital tract, and rectum and when symptomatic can result in a number of
diseases in the first few months of life such as inclusion conjunctivitis, pneumonia or both
[90,91; reviewed in 92; 93). Ophthalmia neonatorum has been reported as developing from
5-14 days post-delivery in up to 50% of infants of C.trachomatis infected mothers [94] and
perhaps even as late as 42 days after birth [94] with between 5-30% of perinatally-infected
infants also having nasopharyngeal infection [reviewed in 95]. A recent prospective study from
Brazil estimated the prevalence of rate of Chlamydia among pregnant women (<30 years) in
their third trimester as 72.7% and reported that 50% of 16 newborn babies had respiratory
symptoms within the first 60 days of life [96].
Afebrile pneumonia may be seen in infants colonised in the respiratory tract with C.trachoma‐
tis and this may/may not be associated with inclusion conjunctivitis. After three or more weeks
following Chlamydial infection of the infants a subacute, afebrile pneumonia with onset at
ages 1–3 months develops in approximately seven percent of these cases [97, 92, 19]. Clinical
characteristics have been described for infant pneumonia caused by C.trachomatis in infants
with nasopharyngeal shedding and in around half of the infected infants conjunctivitis was
recorded, with middle ear abnormalities recorded in more than half of the Chlamydia-positive
infants and wheezing an unusual finding in these infants [98]. A more recent study has also
highlighted that C. trachomatis is an important cause of lower respiratory tract infection in
infants in India below six months of age [99].
1.5. Immunopathogenesis and immunoprotection
The host inflammatory response to C.trachomatis is involved in immunity but also the pathol‐
ogy that leads to serious morbidities of chronic pelvic pain, EP and tubal infertility following
female genital tract infection. Protective responses to C.trachomatis infections of the female
genital tract are elicited to clear primary infection and to resist re-infection and include both
innate and adaptive (particularly CD4+ T cell) cells and immune responses. Cells of both the
innate and adaptive immune systems are found in the FGT in Fallopian tubes, uterus, cervix
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and vagina [100] and we have recently reviewed the localisation of T lymphocyte populations
in the female upper (UGT) and lower (LGT) genital tracts over the menstrual cycle [101].
Effector cells of the innate (non-specific) immune response found in the FGT include epithelial
cells, monocytes, macrophages, granulocytes (neutrophils, eosinophils and basophils),
dendritic cells (DCs) and Natural Killer (NK) cells conferring protection through chemokines,
cytokines and phagocytosis. Innate (non-specific) host defense particularly in the lower genital
tract (LGT) is also provided by the vaginal microbiota maintained in a healthy equilibrium
(reviewed in [102] as well as by the myriad of antimicrobial peptides (AMPs) and protease
inhibitors of cervicovaginal fluid [103] including elafin, lysozyme and cathelicidins, amongst
others and reviewed in (Wira and Fahey, 2004). The AMPs and pathogen recognition receptors
(PRRs) such as toll-like receptors (TLRs) are key intermediaries of innate immunity in the FGT
[104-107]. The innate immune cells (especially neutrophils) elicit inflammation to protect
against infections however these inflammatory responses are usually inefficient and repeated
Chlamydial infections are common [108].
The rapid innate immune response is the first line of defence against a C. trachomatis infection
of columnar epithelial cells. PRRs recognise the pathogen and TLRs play a vital role in the host
immune system by recognizing pathogenic components (pathogen associated molecular
patterns (PAMPs) and danger associated molecular patterns (DAMPs)) and inducing a
protective immune response to the pathogen [109]. Data indicate that host genetic factors may
contribute up to 40% to the variation in clinical course of Chlamydia infection [110]. Host genetic
variants in TLRs have been found to influence Chlamydia LGT infections in women [111]. For
example protection against tubal disease following a C.trachomatis infection has been report‐
edly associated with single nucleotide polymorphisms (SNPs) in the innate immune (TLR)
gene, TLR2 [112]. SNPs in TLR4 have also been reported to play a role in making women more
prone to subfertility (i.e. no pregnancy after 1 year) as a late complication of Chlamydia infection
[113] and worldwide estimates are that 10-15% of all couples are subfertile [114]. SNPs in other
pathogen recognition receptors including nucleotide-binding oligomerization domain
receptors (NODs) have been reported to influence susceptibility and severity of Chlamydia
infections [115]. Taken together these observations have lead to the recent suggested potential
translational and clinical value of adding diagnostic host genetic marker profiles on the basis
of infection and inflammation to the current clinical management of subfertility [116].
The more gradual adaptive immune response to Chlamydial infection is mediated through
antibodies and/or T cells and is a very specific recognition and response to foreign antigens.
Cervical cell production of IFN-g and interleukin-12 (IL-12) in response to stimulation with
C.trachomatis EBs has a positive correlation with fertility in C.trachomatis seropositive patients
[117]. Recruitment and activation of B cell (humoral) and T cell (cell-mediated/adaptive)
immunity is also coordinated by the release of these factors. The initiation of this adaptive
response may lead to spontaneous resolution of natural infection in some populations [25]
although chronic infections in women indicate that rarely does this response to C.trachomatis
result in clearance of the infection; nor does it adequately protect against re-infection. The
cellular components of this specific immunity include T lymphocytes expressing αβ- and γδ-
T cell receptors (TCR) and immunoglobulin (Ig) producing B lymphocytes [reviewed in 101].
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During active primary genital infections in women, serum and genital mucosal IgA and IgG
antibodies to Chlamydial EBs and specific Chlamydial proteins including heat-shock (HSP)
and plasmid proteins are usually detected [118]. AntiChlamydial antibodies are not sufficient
to protect infected females from re-infections [119].
Once Chlamydia has established intracellular infection, cells of the adaptive immune system,
and particularly T helper 1 (Th1) type CD4+ T cells secreting IFN-g are required for clearance
of primary infection and to protect from re-infection [120]. It has been observed from human
data that MHC Class II-restricted CD4+T cells of the Th1 phenotype are critical for the recovery
from primary Chlamydial infection and also have a role in protecting from disease sequelae
[121,122]. Other major lineages of activated CD4+ T cells that play critical roles in Chlamydial
infections include the Th2 cells, Th17 cells (producing IL-17 and IL-23) and Tregulatory (Treg)
cells [123,124]. Additional T cells involved in adaptive immunity include intraepithelial
lymphocytes (γδ T cells) and cytotoxic T lymphocytes (CD8+ T cells) that are known to induce
apoptosis of infected Chlamydial cells [125].
Disease outcomes are dependent upon the complex interactions between virulence factors of,
and evasion strategies used by, C.trachomatis and host immune responses including variants
in genetic markers associated with infection and inflammation. Host factors and cellular
immune responses associated with susceptibility to, or protection from Chlamydial infection
and/or diseases have recently been reviewed [126].
2. Chlamydial genital tract infection and immune regulation by sex
hormones
The FGT comprises several immune compartments found in the UGT (endocervix, ovaries,
Fallopian tubes and uterus) and LGT (ectocervix, and vagina). The UGT is lined with a single
layer of columnar epithelium and the LGT with is lined with stratified squamous epithelium
[100]. The transitional zone where squamous epithelium changes to columnar epithelium is
the most immunologically active site of the FGT [127].
The human FGT contains components of the innate and adaptive mucosal immune responses
that are found in various distributions at different sites throughout the tract. In the FGT the
major lymphocyte components are Natural Killer (NK) cells and T lymphocytes including
CD3+ T lymphocytes that are present in all tissues of the tract. In the LGT the CD8+ and CD4+
are dispersed throughout the stroma whilst lymphoid aggregates of these cells are formed in
the uterus [128]; granulocytes are present and these are principally located in the Fallopian
tubes. Finally, relative to T lymphocytes, smaller numbers of monocytes and B lymphocytes
are found throughout all tissues of the FGT [129].
Host protection of the FGT is afforded by two arms of defense comprising innate (non-specific)
and acquired (specific) immunity. The cellular components of the specific immune responses
at this site are T lymphocytes expressing αβ- and γδ-T cell receptors (TCR) and immunoglo‐
bulins (Ig) producing B lymphocytes [130]. Effectors of non-specific responses include
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epithelial cells, monocytes, macrophages, granulocytes (neutrophils, eosinophils and baso‐
phils), dendritic cells (DCs) and Natural Killer (NK) cells that confer protection due to
chemokines, cytokines and phagocytosis. Cells of both the innate and adaptive immune
systems are found in Fallopian tubes, uterus, cervix and vagina [131].
Both innate and adaptive mucosal immunity in the FGT are regulated by the female sex
hormones estrogen (E2) and progesterone (pregn-4-ene3,20-dione) or (P4) and have been
reviewed [130, 132, reviewed in 101]. Hormones regulate the transport of Igs, levels of
cytokines, expression of Toll-like receptor (TLR) genes [133,134] and the distribution of
immune cells and antigen presentation in the genital tissues during the reproductive cycle.
Estradiol regulates the structure and function of the FGT via the classic model of steroid action
(‘i.e. genomic regulation) which is mediated by activated nuclear receptors including estrogen
receptors (ER)-α and ER-β [131,135]. Estradiol can also exert rapid “non-classic” steroid effects
on diverse signalling pathways and second messenger systems that occur independently of
transcriptional or classic genomic regulation [136]. These rapid responses are often referred to
as ‘non-genomic’ steroid effects and they can affect genital tract cells and innate and humoral
immunity at this site which may alter the pathogens ability to infect the genital tract [137].
The recruitment and function of immune components of the FGT are precisely regulated by
hormonal changes during the menstrual cycle by the sex steroids that co-ordinate cell traf‐
ficking and immune activation at this mucosal site. Female sex hormones E2, progestins and
androgens are produced by ovarian cells with levels of estradiol (17β-estradiol) and P4 varying
in accordance with fluctuations in the menstrual cycle [130]. In the menstrual/ovarian cycle of
humans the endometrium develops and follicles grow until ovulation in the Proliferative/
Follicular phase. The Secretory/Luteal phase is characterised by high levels of progesterone
from the corpus luteum to maintain the endometrium. Finally, corpus luteum regression and
menstruation occurs during the menstrual phase At menstruation, serum estradiol levels
measure typically <50pg/ml. Gradually increasing amounts of estradiol are found in the
follicular (proliferative) phase of the adult female menstrual cycle with serum levels at a pre-
ovulatory stage (day 14) ranging from 110-410 pg/ml and dropping briefly at ovulation. Levels
of estradiol (20-160pg/mol) and P4(>5ng/ml) are present during the luteal (secretory) phase
from days 14-28 of the menstrual cycle typically peaking at day 21 of the cycle. At the end of
the secretory phase estradiol levels return to their menstrual levels.
The innate response is triggered by PRRs (including TLRs and non-TLRs such as NOD-
like receptors) expressed predominantly by innate immune effector cells such as macrophag‐
es, neutrophils and DCs that are found in the genital mucosa. Human oviduct epithelial
cells (ECs) express Toll-like receptor 3 and E2 has been reported to suppress the TLR-3-
induced cytokine and chemokine production in human endometrial epithelial cells [138].The
effects of E2 on the differentiation and function of antigen-presenting cells (APCs) in vitro
has been reviewed (see [139; 132]. Much of the current evidence shows that E2 can activate
dendritic cells and differentially regulate adaptive immune responses through direct effects
on DC functions [140] via E2 receptor (ER) ligands [141]. These include TLR4 and its co-
receptor Cluster of Differentiation (CD) 14 (Chlamydial LPS and Chlamydial HSP60) [142;
143;  144]  TLR2  (Chlamydial  HSP60)  [145,146]  and  NOD  protein,  Nod2  (rudimentary
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proteoglycan motif produced by C. trachomatis and C.muridarum) [147]. Expression of TLR
genes  2,3,4,5,6,9  and  10  is  reportedly  significantly  higher  in  human  endometrial  tissue
during the secretory phase (when P4 is the predominant hormone) compared to all other
phases of the menstrual cycle [148].
Changes in the populations of DC and macrophage cells in the murine FGT occur due to
varying levels of ovarian steroid hormones at this site in the model [149], and in women,
changes in these cell populations occur due to the varying stages of the menstrual cycle,
noting that the frequencies of macrophages and immature DCs are higher in the menstru‐
al  phase  when  compared  to  all  other  phases  of  the  cycle  [150,  151].  CD16-expressing
macrophages and monocytes are also key components of the innate immune system of the
FGT and are cells that are capable of producing cytokines and chemokines upon activa‐
tion. These cells are also known to be profoundly affected by E2 [reviewed in 152]. Studies
have shown that E2 uses both estrogen receptor (ER) alpha (ERα) and ER beta (ERβ) to
decrease  CD16  expression  on  monocytes  and  hence  to  alter  monocytic  cytokine  release
following CD16 receptor activation [153].
T lymphocytes present in the FGT, specifically CD4+ and CD8+ T cells, and immune mediators
of cell-mediated immunity are found distributed within distinct regions of the female LGT.
The normal vaginal mucosa contains T cells and APCs with the few immune cells present
consisting primarily of CD1a+ DCs and CD8+ intraepithelial lymphocytes (IELs) [154]. The
tissues in the UGT have been found to express a greater number Th1-associated chemokines
than the tissues in the LGT comprising the cervical-vaginal region [153]. The menstrual cycle
and menopause have been reported to have no apparent effect on cellular localization or
abundance of T lymphocyte subsets and APCs in any of the lower genital tract tissues [127].
In humans, expansion of human CD4+CD25+ regulatory T cells (Tregs) has been reported to
occur in the late follicular (proliferative) phases of the menstrual cycles of fertile women [124].
Levels of IgG and IgA antibodies in FGT fluids are also known to be modulated by the stage
of the menstrual cycle in women. E2 up-regulates the in vitro expression in the FGT of secretory
component (SC) increasing transport of IgA into the lumen [154] and transport of polymeric
IgA (pIgA) into FGT tissues is significantly decreased by ovariectomy, although this decline
can be reversed by addition of E2 but not P4 [155]. The effects of ovarian hormones on
immunoglobulin secreting cells (ISC) function in healthy women were also investigated and
it was reported that ISC frequency in peripheral blood mononuclear cells (PMBC) was highest
during the peri-ovulatory stage of the menstrual cycle [156].
2.1. Sex hormones and chlamydial infection
It is becoming increasingly well documented that sex hormones E2 and P4 regulate host
susceptibility, as well as innate and adaptive immune responses to the sexually transmitted
pathogen Chlamydia infecting the mucosal surfaces of the FGT [reviewed in 101].
Data from several animal models of genital tract Chlamydial infection have shown that
Chlamydial infection may be influenced by timing of exposure and the steroid status of the
mucosal epithelium. In the murine model of C.muridarum infection pre-exposure of the animals
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to P4 is required to achieve maximal infection outcomes in the animals [157]. However,
treatment of female guinea pigs with E2 resulted in Chlamydia caviae infections of greater
intensity and longer duration [157-160] an effect that it also observed following oral contra‐
ceptive administration to these animals [161]. In the female reproductive tract rat model it was
reported that no Chlamydial inclusions were detected in either the uterus or vagina in rats that
had been infected with C. trachomatis (mouse pneumonitis strain MoPn) at estrus and diestrus
without prior P4 priming [162]. In rat studies it has also been reported that when ovariectom‐
ized animals were administered estradiol, progesterone, or a combination of both and infected
with Chlamydia trachomatis via the intrauterine route no Chlamydiae were found vaginal
secretions of E2-treated animals nor were there any signs of uterine or vaginal inflammation
in these animals [163].
Additionally, the use of in vitro cell lines to investigate C. trachomatis infection have produced
data showing that the hormonal status of the epithelium can influence the outcome of
Chlamydial infections in these models. It was shown that E2 treatment of HeLa cells pre-
infection with C.trachomatis (serovar K or L1) enhanced both of adherence of EBs to the cells
as well as Chlamydial inclusion formation; post-infection, the presence of E2 was required for
the enhancement of inclusion formation [164]. Using a hormone responsive human endome‐
trial cell line an association between repeated Chlamydial infections in women and high levels
of E2 has been reported [165]. More recently it has been reported that the sex hormones E2 and
P4 can directly modulate Chlamydial genes associated with persistence (the viable but non-
culturable state in the Chlamydial developmental cycle) in the host. It is likely, however, that
the major effects of these hormones on Chlamydial infection are indirect via the host cells [166].
The outer membrane complex B (omcB) and tryptophan B (trpB) genes are two of several
reliable markers for Chlamydial persistence [167,168]. It was reported that in E2-supplemented
cultures of C.trachomatis serovar D infections of a hormone-responsive human endometrial cell
line, an up-regulation of the omcB and trpB genes was observed suggesting a stress response
indicative of Chlamydial persistence; morphological changes (aberrant, enlarged RBs) were
also observed in these cultures consistent with a persistence response [166]. P4-supplemented
cultures resulted in a general up-regulation of genes encoding amino acid and carbohydrate
metabolism pathways [166].
Chlamydia trachomatis infection of the female LGT stimulates innate immune cells by activation
of TLR2/TLR4 [reviewed in 169]. TLRs 2 and 4 have been found at the highest expression levels
in endometrium and Fallopian tube tissue [170] with the predominant expression of TLR4 and
its co-receptor CD14 in the Fallopian tubes proposed to play an important role in the innate
host defence mechanism against ascending C. trachomatis infections [169,171]. In a recent study
C.trachomatis-infected women have been reported to express higher TLR2, TLR4 and inducible
nitric oxide synthase (iNOS) in their cervical monocytes compared to controls. It is thought
that TLR4 initiates the innate immune response to Chlamydial infection, activation of TLR2
leads to expression of inflammatory cytokines whilst iNOS contributes to Chlamydial
clearance from this mucosal site [172]. Recently it has been reported that E2 reduces TLR4
expression of human monocyte derived Dendritic cells and suggested that this may increase
host susceptibility to C. trachomatis infections [173].
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Studies of C.trachomatis infections of the FGT have reported many effects of hormones on
infection and immunity to the pathogen at this mucosal site. For example significant increases
in the sensitivities of cervical epithelial cells to infection with C.trachomatis occur in the later
stages of the female menstrual cycle [174]. It has been reported that Chlamydial infection
occurring in the early E2-dominant phases of the cycle was a significant predictor for devel‐
opment of salpingitis [175]. Clinical findings have also reported on the enhancing effects of E2
on Chlamydial infection and disease sequelae in the infected female genital tract. It has been
reported that women are more susceptible to Chlamydial infection under the influence of E2
[165]. In women with fertility disorders (n= 115) and in women with C.trachomatis mucopur‐
ulent cervicitis (n=86) a significantly positive correlation was recorded between Chlamydial
load and E2 levels [117].
Chemokine receptors direct T lymphocytes to the site of mucosal infection, including infection
of genital tract epithelial cells with C.trachomatis and these receptors can be modulated by E2.
In a study examining samples from human patients it was reported that CCR5 (chemokine (C-
C motif) receptor 5) expression increased followed C. trachomatis genital infections [125].
Reproductive hormones may potentially act with cytokines to regulate immune responses in
the FGT to Chlamydial genital tract infections in vivo. Significant negative correlation has been
reported between E2 levels in women with primary Chlamydial genital infections and cervical
wash concentrations of IL-10, IL-1beta and IL-6 cytokines. Significant negative correlations
were also recorded between IL1-beta cytokines and P4 levels in women with recurrent
Chlamydial infections [176]. Thus it would appear that Chlamydial infection of the human
FGT is modulated in part by the combined actions of cytokines with E2 and P4. More recent
investigations reveal that levels of E2 were significantly higher in Chlamydia-positive women
with fertility disorders when compared to fertile women suggesting that this sex hormone
contributes to development of disease sequelae to C.trachomatis infection of the FGT[165].
E2 has been reported to exacerbate Chlamydial infections in women following administration
of oral contraceptives [177] an observation also noted for female guinea pigs [161]. A prospec‐
tive study on oral contraceptive pills or depo medroxyprogesterone acetate and sexually
transmitted disease acquisition reported that women using oral contraceptive pills were at
increased risk for acquisition of Chlamydia [178]. Hormonal contraceptive use in women,
particularly depo medroxyprogesterone (DMPA), has also been reported in observational
studies to be associated with a four-fold increase in Chlamydial genital tract infections [179].
3. Immunopathogenesis — chlamydial infections, tubal factor infertility,
ectopic pregnancy and pid
A primary Chlamydial infection of the FGT can elicit host immune responses that are involved
both in immunity to infection and in pathology of disease. Innate immune responses constitute
the first line of defence against pathogens and include TLRs that are expressed in the FGT.
Further, although the host immune response affords protection against infection via means of
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rapid and efficient bacterial destruction, resultant inflammatory responses may lead to tissue
damage and/or persistent infection.
In reaction to Chlamydial entry in host cells, innate immune responses occur at the infected
mucosal site 1-2 days post infection [180]. Intense inflammation and predominant mucosal
infiltration of phagocytes, neutrophils and macrophages ingest and enzymatically destroy the
bacteria. In conjunction with the production and subsequent activation of phagocytic cells,
others, crucial to infection resolution are also activated [181]. Natural killer (NK) cells are
activated in direct response to C. trachomatis infection or indirectly by macrophagic stimulation
of IL-12, a potent NK cell-triggering cytokine. Once activated, NK cells produce IFN-g which
stimulate macrophages, further promoting phagocytosis. Innate immunity may impede
infection, however, the inaccessibility of Chlamydia to circulating antibodies whose sole
purpose is elimination necessitates adaptive immune effector mechanisms of both humoral
and cell-mediated immunity.
Activation of cell-mediated immunity post infection is demonstrated by the proliferative
response ratio of peripheral blood lymphocytes to Chlamydial EBs. T cells, which functionally
differentiate into Th1 or Th2 subtypes based upon cytokine secretion profiles, also amass at
the infection site [182]. Further, interaction of C. trachomatis with the cytokine network is a key
component for resolution of infection and one in which a cytokine response is elicited either
through direct infection of epithelial cells or by host cell interaction. In concert with the
inflammatory process, tissue repair, comprising the removal of dead cells and the ingrowth of
fibroblasts, leads to scar formation and potential impairment of Fallopian tube function [183].
Moreover, all three tubal layers i.e. interstitial, muscular and serosal may be implicated in scar
development. Infection of the serosal layer elicits an inflammatory exudate, present on the
peritoneal surface, thereby adhering all adjacent surfaces and structures. Although the innate
and adaptive immune responses systematically co-ordinate their efforts to ultimately resolve
infection, the immune response to Chlamydial infection can cause deciliation of tubal epithe‐
lium, intralumineal adhesions, tubal occlusion and peritubal adhesions. As a result, such gross
anatomical and pathological changes may lead to infertility, EP and possible spontaneous
abortion [184].
Primary Chlamydial infections of the FGT thus induce both innate and adaptive host immune
responses that contribute to clearance of the infections. However, results from a 5-year study
of natural genital Chlamydial infections in women strongly suggested that C. trachomatis
infection was cleared from the cervix epithelium in only 54% of the women at 12 months [185].
This low clearance rate is due, in part, to the organism’s ability to utilise various mechanisms
with which to evade the host immune system. In fact rarely do host immune responses to
Chlamydia induce a total clearance of genital infections. Indeed, the women remaining infected
in the genital tract with C. trachomatis are unable to mount strong adaptive immune responses
to clear the pathogen hence they become asymptomatic and remain undiagnosed with a
persistent Chlamydial infection. Chronic inflammation resultant from a persistent C. tracho‐
matis infection can lead to a wide spectrum of disease manifestations. In persistently-infected
Chlamydial host cells, inflammatory cytokines are released in response to the latent infection
to aid in the eradication of the pathogen. Unfortunately, these cytokines, which act as immu‐
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nomodulators may in fact, induce and sustain tissue damage and host inflammatory responses.
Compounded with repeated infections, the continued production of cytokines may cause
serious disease sequelae such as PID, TFI, chronic pelvic pain or EP. Chlamydial Hsp60
(cHsp60), a known potent inducer of host inflammatory responses, may protect against
Chlamydial infections [186]; paradoxically, however, cHsp60 is also able to induce pro-
inflammatory responses, which can lead to tissue damage in women infected with C. tracho‐
matis [187-189].
Recent data from a prospective study of 30 women diagnosed with a ruptured EP demon‐
strated that anti-cHsp60 immunity confers a higher risk of EP [190]. Furthermore, in those
women who were positive for anti-cHsp60 antibodies and suffered an EP, all had significantly
lower IL-1β levels than Chlamydial sero-negative EP cases [190]. Importantly, high serum
concentrations of IL-1β in the Fallopian tubes correlated with successful uterine implantation
of embryos [191-192]. Data obtained from a prospective cohort of women at high risk for C.
trachomatis infection demonstrated that a Th1 response i.e. the release of IFN-g to cHSP60 was
associated with protection against the bacterial infection [186]. In contrast, it was also shown
that an IL-10 response to the same Chlamydial antigen increased infection risk. In a study that
investigated cytokine responses of cervical mononuclear cells obtained from 153 women all
serologically positive for C. trachomatis, it was found that exposure to cHsp60 and cHsp10 may
drastically affect the host’s mucosal immune function by increasing the production and
subsequent release of IFN-g, IL-10 and tumour necrosis factor-α (TNF-α) [193] thereby
potentiating further tissue damage and disease sequelae.
TLRs are responsible for initiation of the adaptive immune system, thereby leading to the
ultimate destruction of foreign microbes. Moreover, since they recognise structurally con‐
served molecules from various bacteria, they play a vital role in host defence. Chlamydial-
induced PID was investigated and it was reported that among women clinically diagnosed
with PID, those who carried variants in TLR 1 and TLR 4 genes had significantly increased
odds of C. trachomatis infection [191]. In a more recent study, it was concluded that racial
variation in TLR variants amongst women with PID may alter signalling pathways subsequent
to microbial recognition, thus causing an increase in associated inflammation [194]. An
investigation of pregnant women positive for C. trachomatis showed that those with serological
evidence of prenatal C. trachomatis infections were more likely to develop pre-eclampsia [192].
Polymorphic membrane proteins (Pmps) represent 13.6% of C. trachomatis’ entire coding
genome [195], therefore inferring a potential role in Chlamydial biology and virulence. In a
group of 40 C. trachomatis-infected women with clinically diagnosed mild to moderate PID,
antibody levels of PmpA, PmpD and PmpI were evaluated. Interestingly, those women with
PmpA antibodies were less likely to fall pregnant (p=0.042) and achieve a live birth (p=0.005)
compared with those sero-negative for PmpA [196] suggesting that the immunopathological
damage may indeed be a result of PmpA virulence. Further, it was also reported that women
who were sero-positive for PmpI antibodies had a higher incidence of upper genital tract
infection (p=0.026). However, antibodies to PmpD and PmpI did not alter the risk of FGT
inflammation or sequelae.
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One of the most important and common long-term complications of Chlamydial PID is TFI.
Numerous studies have demonstrated serological evidence of prior C. trachomatis infection is
associated with TFI [197-201]. An investigation conducted by the World Health Organisation
(1995) of TFI rates as a consequence of C. trachomatis or N. gonorrhoeae-induced PID showed
that C. trachomatis-induced PID was associated with a higher incidence of TFI when compared
to PID caused by N. gonorrhoeae. A retrospective study of 1844 women all laparascopically
diagnosed with PID due to C. trachomatis showed that 209 (16%) failed to conceive [202]. Of
these, confirmed TFI was established in 141 patients with PID. Importantly, the rate of
infertility was directly associated with the number and severity of PID infections. Specifically,
every subsequent episode of PID approximately doubled the rate of TFI i.e. 8% upon one C.
trachomatis infection, to 19.5% from two exposures resulting in infection and an increase to 40%
resultant from three or more exposures.
In a more recent study that evaluated cHsp60-specific antibody and cell-mediated responses
as predictors for TFI [201] it was reported that C. trachomatis-specific IgG antibodies were more
common in TFI patients (43.2%) when compared to the control group (13.5%), thus suggesting
C. trachomatis may play a significant pathogenic role in the development of TFI. To elucidate
the clinical variability of TFI caused by C. trachomatis, functional polymorphisms in various
cytokines were assessed [203]. The study showed that allelic variation in IL-10 and TNF-α
increased the risk of severe tubal damage in women diagnosed with infertility caused by C.
trachomatis. Similarly, a more recent study demonstrated that variation in the IL-12B gene was
associated with increased susceptibility and TFI severity [204]. Interestingly, polymorphic
changes in IL-10 and IFN-g appear to be linked with a more intensive lymphocytic proliferation
in response to C. trachomatis antigens [205]. Antibody production following cHSP60 exposure
was found to be significantly higher in those women (n=21) clinically diagnosed with TFI [206].
Furthermore, elevated antibody levels to caseinolytic protease P, a proteolytic subunit of the
ATP-dependent Clp protease complex involved in the degradation of aberrant proteins, was
also demonstrated in TFI patients. Serum levels of IgG1 and IgG3 antibodies against chlamy‐
dial major outer membrane protein (MOMP) and cHSP60 were shown to be elevated in women
(n=70) with TFI compared with the control group (n=92; normal Fallopian tubes and sero-
negative for Chlamydia) (p=<0.001) [207]. A study that evaluated the potential association of
anti-Chlamydial IgM antibodies and TFI showed that of the 50 women assessed, 60% were
sero-positive [208]. Of these, 52% presented with bilateral tubal blockage, which was more
commonly detected in the ampullary portion (36%) of the Fallopian tube.
4. Immune responses, protection and pathology of chlamydial genital tract
infections
Chlamydia (serovars D-K) infects epithelial cells lining the FGT with primary infection estab‐
lishing in the endocervix [209]. If not controlled, primary infection can ascend the reproductive
tract leading to the establishment of infection within the endometrium and Fallopian tubes.
The kinetics of ascension of Chlamydia to the URT is unclear. Although Chlamydia can be
transported via attachment onto sperm, the demonstration that small particles (the size of
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sperm) when deposited into the vaginal vault, rapidly ascend up into the uterus within 2 mins
suggests as the general flow of fluids within the FGT may facilitate ascending infection [210,
211. For most women natural immunity appears to take a long time to acquire - if at all. As
previously noted in a study by Molano and colleagues, it was demonstrated that 50% of women
continue to shed the organism one year after infection is first documented, and 5 to 10%
continue shedding even 3 years later [13]. There is limited evidence to suggest that the
generation of natural immunity occurs in some individuals. A number of studies have reported
that in around 20% of cases, spontaneous resolution of infection occurs [212,213]. As mentioned
previously, Giesler and colleagues showed that women with spontaneously resolved genital
infections were less likely to be re-infected within twelve months [25]. The host’s immune
factors associated with the spontaneous resolution of infection are yet to be elucidated.
Unfortunately, any natural immunity induced following primary infection appears to be short-
lived and serovar-specific resulting in many re-infections [214-217]. Animal models of
Chlamydial genital tract infection have shown that the generation of Th1 cell mediated
immunity is characterized by a strong IFNγ and TNFα cytokine production and that this strong
response is essential for clearance of primary Chlamydial genital infections [218-220]. The
observation that B cell deficient mice can resolve a primary infection suggests that antibodies
play a non-critical role in protection [100]. However, B cell responses are important in resolving
secondary infections. The generation of Chlamydia specific antibodies that are able to neutralize
bacteria preventing infection have been reported in various cell lines in vitro [221-223] and in
vivo [224]. CD4+ T helper cells induced during primary infection mediate affinity maturation
of antibodies, Ig class switching, and B cell memory responses during subsequent infection.
Therefore, B cell memory and antibody production in the presence or absence of CD4+ cells is
critical for the prevention of Chlamydia reinfection [225-227] In addition, results from murine
studies show the infiltration of immune cells, including CD8+ T cells, B cells, neutrophils and
dendritic cells is associated with clearance both of intracellular and of extracellular Chlamydial
bodies [228, 117, 229,230]. Using cytobrush sampling of women, an increase in neutrophils,
dendritic cells and lymphocytes (CD4+ and CD8+) was reported during Chlamydia infections
in these woemn [125,231].
Chlamydia infection of endocervical cells results in an increase in pro-inflammatory cytokine
and chemokine production such as IL-1, IL-8, IL-12, IL-6[232, 233, 209]. Live C. trachomatis is
innately recognized by pattern recognition receptors (PRRs) including Toll-like receptors and
nucleotide-binding oligomerization domain (NOD)-like receptors. Both TLR2 and TLR4 are
highly expressed in female genital tissues and have shown to be activated by live Chlamydia
[234]. The myeloid differentiation primary response gene (MyD)88 is essential for nuclear
factor–κ-β (NFκβ) signalling and transcription of pro-inflammatory cytokines and along with
TLR2, MyD88 has been shown to co-localize within the intracellular Chlamydial inclusion
during infection [235]. Mouse TLR2 knockout animals produce lower TNFα and macrophage
inflammatory protein-2 (MIP-2) and report a significant decrease on oviduct pathology and
hydrosaphinx, suggesting a major role for TLR2 in pathogenesis [236]. The direct activation of
another PPR NOD-1 by Chlamydia results in the production of IL-8, which is produced at high
concentrations during infection and recruit neutrophils to the genital tract [237, 238]. Overall,
cytokine production during infection mediates the recruitment of innate immune cells that
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secrete IFNγ and TNFα. These include natural killer (NK), Dendritic cells and neutrophils
[239, 229]. The recruitment of innate immune cells and cytokine production is linked to upper
reproductive tract pathology and scaring leading to the development of tubal infertility and
ectopic pregnancy. In particular, Hvid and colleagues reported that during a C.trachomatis
infection the production of IL-1 from Fallopian tubes biopsies led to the destruction ciliated
epithelium. Furthermore IL-1 production additionally induced IL-8 production from Fallopian
tube epithelial cells thereby potentially meditating the recruitment of neutrophils to this site
[232]. The development of a chronic or persistent Chlamydia infection would induce continued
production of innate immune mediators perpetuating cellular recruitment leading to epithelial
damage, scaring and disease. The innate immune cell generation of immunopathogenesis and
disease is termed the cellular paradigm [182].
Following clearance of a primary Chlamydia infection, re-infections are common in women;
moreover, re-infections are strongly associated with development of pathology in these
women. Results from animal models of Chlamydial infection have shown that during re-
infection T cells are present within the URT at a higher magnitude than in primary infection
[240]. Chlamydia has shown to act as both an immunizing and sensitizing infection. Non-human
primate vaccine trials have shown that immunization with whole cell organisms led to
hypersensitivity and an increase immunopathogical response leading to greater scaring in an
ocular model. This suggests a specific role for adaptive responses in pathology and this is
termed the immunological paradigm. Although the specific mechanism or causative antigen
in unknown, it is hypothesized that during re-exposure pathogenesis is associated with either
delayed-type hypersentitivity (DTH) or molecular mimicry causing autoimmunity [241]. DTH
is hypothesized to be associated with persistent Chlamydial infection. During latent infections,
low level antigen specific immune stimulation is believed to contribute to chronic inflamma‐
tory cell infiltration [242]. A role for antigenic sensitivity associated with DTH has been
observed in animal models. Guinea pigs sensitized with Triton-X-100 soluble EBs and monkeys
sensitized through immunization with a whole Chlamydial vaccines both reported the
generation greater inflammation and DTH during re-exposure compared to un-sensitized
controls [243,244]. In additon to DTH, autoimmunity may play a role in pathogenesis through
the mechanism of molecular mimicry. Chlamydial HSP-60 (cHSP60) shares similar homology
to self HSP-60 with recent evidence showing that C. trachomatis HSP-60 contains four T-cell
epitopes that display identity with human HSP-60 [245, 246].T cell stimulation by self HSP-60
when pre-immunized with cHSP60 is characterized by the production of pro-inflammatory
IFN-g. In contrast, pre-immunization and and re-exposure with self HSP60 results in the
production of the anti-inflammatory cytokine IL-10 [247] although previous studies have
shown that T cells isolated from patients with PID and TFI respond to cHSP-60 stimulation,
and the presence of cHSP-60 specific antibodies correlate with the severity of PID and TFI
pathology [248,188]. A recent study by Ness et al., showed that increased cHSP60 antibody
titres are not associated with the development of PID [249]. Further the presence of strong
cHSP60 T cell IFN-g has more recently been shown to predict protection rather than pathology
during reinfection [250]. The conflicting association of cHSP60 with protection or pathology
is indicative of a balance between specific cell mediated responses leading to protection or
pathogy.
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Recent evidence has shown that the Chlamydial plasmid may play a role in generating
pathology during infection. As mentioned earlier, almost all C. trachomatis isolates contain a
7.5 kB cryptic plasmid although plasmid-free isolates have been shown in genital serotypes
L2, D and E [43-45]. During infection of mice with plasmid-cured C. muridarum strains a strong
Th-1 cell response is induced however immune pathology and tissue damge is not observed
[41] Further, plasmid cured C. muridarum or C. trachomatis strains do not stimulate the pro‐
duction of cytokines though TLR2-dependent activation in vivo and in vitro respectively [251].
In contrast, Frazer et al showed that in the guinea pig model, a plasmid cured C. caviae strain
both signals through TLR-2 and induced post infection pathology suggesting that the associ‐
ation of the Chlamydial plasmid with virulence is not universally conserved among Chlamydial
species [252]. Importantly, murine studies have shown that previous infection with plasmid-
free is protective against the development of immunopathology with subsequent infection
with a virulent strain [41]. This has lead to the use of plasmid-cured strains as attenuated
Chlamydial vaccines in mouse and primate models of infection [41, 253].
Overall, the natural history of Chlamydial infections in women varies in which some untreated
individuals with untreated infections persist for long periods asymptomatically and progress
to cause pathology and disease, while others spontaneously resolve infection. Although the
mechanisms are yet to be fully elucidated, there are currently two proposed mechanisms for
the development of pathology in the female reproductive tract; the cellular and the immuno‐
logical paridigms that are associated with innate and adaptive responses respectively. Further,
these mechanisms are not mutually exclusive and may both play a role in the development of
upper reproductive tract pathology and disease during primary and subsequent infections.
The recent identification of plasmid-free strains associated with induced protection against
immunopathology may provide a mechanism for immune stimulation leading to pathology
and disease.
5. Past and present treatments, how to improve local immunity and future
vaccine developments
5.1. Antibiotic treatment
Chlamydia infection of the FGT is largely asymptomatic with approximately 80% of women
observing no reported symptoms [254]. Whilst there are no specific genital symptoms
associated with Chlamydial cervical infection, 37% of women who develop cervicitis observe
mucopurulent discharge and in 19%, hypertrophic ectopy (Distinctive oedema of the columnar
epithelium in the female endocervix) [29, 62, 255]. Due to the asymptomatic nature of infection
in the reproductive tract many infections remain undetected and therefore, untreated.
Chlamydial infections, if symptomatic, can be treated through the administration of antibiot‐
ics. The current recommended antibiotic for treatment are either a single dose (1g) azithro‐
mycin or 7 day treatment with doxycycline (2x100mg per day)[256]. Other drug treatment
programs used to treat Chlamydia infections in humans include erythromycin base, (4x500mg
per day for 7 days), or erythromycin ethylsuccinate (4x800mg per day for seven days).
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Erythromycin is effective against Chlamydia infection in the FRT however its use is associated
side effects that may limit compliance [256]. Likewise, Levofloxacin (1x500mg per day for 7
days) and ofloxacin (2x300mg per day for 7 days) are effective for treating Chlamydia infections
but are expensive compared to other alternatives [256]. Following antibiotic treatment it is
recommended that treated persons abstain from sexual intercourse for 7 days to prevent
spreading the infection to partners which may lead to subsequent re-infections [41]. Partner
notification and partner treatment are also important targets to halt re-infections.
Although antibiotics are an effective treatment option, they have been shown to be less effective
in cases of well-established chronic Chlamydial infections. Early reports determined that the
current treatment of azithromycin and doxycycline are more that 95% effective at clearing
Chlamydia genital tract infection [257, 259]. However, recent strong evidence suggests that
antibiotic treatment failure could be greater than the 5% previously reported when accounting
for re-infection [260]. A major hurdle in measuring the rates of antibiotic treatment failure is
the inability to distinguish between recurrent infections and re-infection from infected
untreated or new sexual partners [261]. Discrepancies in the proportion of treatment failures
have been directly associated with testing methods used. Most of the published work inves‐
tigating treatment failure involved tissue culture as a means to detect infection, which has now
been predominately replaced with nucleic acid amplification testing (NAAT). Tissue culture
is less sensitive and has shown to be less effective at identifying small numbers of persistent
bacteria leading to an over estimation of successful Chlamydia eradication following treatment
[257,262]. In a recent study by Batteiger et al (2010) investigating post treatment infection in
adolescent girls, it was observed that 7.9% of those sampled developed recurrent infections
following azithromycin treatment which was not attributed to reinfection [263]. Similarly,
Goldern et al (2005) study in women without the risk for re-infection showed a recurring
infection rate of 8% following azithromycin at 3-19 week follow-up representing treatment
failure.[264]. Current studies argue that previous rates of antibiotic treatment failure of less
than 5% were underestimated due to the available information at the time and that a true rate
of treatment failure of may be greater than 8%. One major concern associated with increasing
antibiotic failure is the development of antibiotic resistance. However, unlike other organisms
such as Staphylococcus, to date there is no evidence of natural and stable antibiotic homotypic
resistance (genetically inherited) in vivo in Chlamydial strains collected from human genital
tract infections [265].
Contributing to antibiotic treatment failure in Chlamydia infections is the phenomenon called
heterotrophic antimicrobial resistance. Heterotrophic resistance refers to the replication of
heterogeneous population containing both resistant and susceptible bacteria from a subculture
of a single resistant organism propagated on antimicrobial-containing medium, that is not
genetically inherited [266]. It is hypothesized that at high bacterial loads a small population of
Chlamydia organisms survive, potentially due to an innate ability to establish a latent/persistent
infection [266]. Importantly these isolates at low loads do not show altered antibiotic suscept‐
ibility or increased resistance due to genetic changes [267]. Latent, non-replicating, non-
infectious aberrant RBs associated with persistence can survive within host cells for extended
periods of time at which infectious organism can not be isolated or able to be cultured.
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However, latent bodies can revert to infectious organisms leading to a recurrent infection. In
vivo persistent infections in women are supported by the observation that some positive
samples obtained using Chlamydia-specific DNA or antigen specific testing do not report the
presence live infectious EBs via cell culture [268-270]. Furthermore, alternating infectious and
persistent phases of Chlamydial growth correlate with acute and chronic infections in vivo
[271]. During Chlamydial infection in women, a large variation in bacterial load has been
observed in the genital tract and antibiotic failure due to heterotrophic resistance is associated
with high bacterial loads [272, 273]. West et al (2005) showed that 91% of individuals with a
low load at baseline observed no infection at follow up (2 months), whereas 74% percent of
individuals with high bacterial load reported no follow up infection [274]. The development
of persistent bodies in vivo during high bacterial load may be an important mechanism driving
antibiotic failure, as these slow growing aberrant forms of Chlamydia may be less susceptible
to antibiotic therapy. In vitro studies have shown that antibiotic treatment directly induces the
presence of non-cultivable Chlamydia that can be reactivated with the withdrawal of treatment.
In vivo the re-emergence of the active infectious form from persistence may take a number of
weeks or months in which previous short term (<3 weeks) follow up testing via culture
methods would provide a false negative result. Likewise false positive results may arise post-
treatment due to persistent DNA detected through NAAT testing [275]. As such, one recom‐
mendation is that follow up screening > 5weeks post treatment is implemented for screening
programs to determine treatment failure [259]. Estimating a true rate of treatment failures is
complicated as many re-current infections remain unreported due to the asymptomatic nature
of infections coupled with a lack of follow up testing in many screening and treatment
programs.
5.2. Are screening and treatment programs leading to arrested Chlamydia immunity?
In many western countries, screening and antibiotic treatment programs for early detection of
Chlamydia have been implemented over the past ten years. The goal of these programs is to
reduce Chlamydia transmission leading to the long-term prevention of disease sequelae,
including PID and infertility. Chlamydia infections are most common among young people
accounting for approximately 80% of all infections. The United States Center for Disease
Control (US CDC) estimates that in the United States alone, one in 15 sexually active females
aged 14-19 years has Chlamydia. Due to this high burden, the US CDC recommends annual
screening for all sexually-active women under 26 years of age [276]. As such, most programs
have been specifically targeted towards young women with a focus to identify and treat
asymptomatic infections. In addition, these programs seek to promote partner notification and
treatment to prevent subsequent re-infection. Although screening and treatment programs
coupled with aggressive education and health programs have been implemented in many
countries for over a decade, Chlamydia rates have continued to increase. For example, the US
CDC reported an increase of 9.7% of Chlamydial infections between 2007 and 2008 [277]. This
increasing trend has also be reported in many countries where long term screening and
treatment programs have been in place including Sweden, Canada, the United Kingdom and
Australia [278-281. Interpreting this increased prevalence or incidence of Chlamydia in the
population requires caution and some argue that increases are directly associated with
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increased testing rates and detection associate with easy home sampling and the development
of the more sensitive nuclear acid amplification test in the 1990’s.
However, it has been hypothesized that an increase in Chlamydia prevalence worldwide at a
time of aggressive screening and testing programs is associated with ‘arrested immune
hypothesis’ [24]. The ‘arrested immune hypothesis’ states that early detection and treatment
of Chlamydia actually impairs the development of natural immunity in these antibiotic treated
individuals. A recent study by Giesler et al (2013) supports the concept of antibiotic treatment
may attenuate protective immunity against reinfection. This work showed that women with
spontaneous resolution of Chlamydia infection were four times less likely to be re-infected
compared to women with infections cleared by azithromycin treatment [25]. The potential
hampering of protective immunity development through antibiotic treatment is believed to
be the associated an increased Chlamydia re-infections. In the province of British Columbia,
Canada, Chlamydia screening and treatment programs have been in place since 1991. Here they
have reported a 5% increase in the re-infection rate over the course of the program [282].
Moreover, re-infection rates were reported to be greatest in young women and potential
increased risk of development Chlamydial disease sequelae. The emergence of antibiotic
resistant organisms, development of persistence, poor patient compliance and high re-
infection rates has highlighted the need for an efficacious vaccine to halt the spread of infection
throughout the population.
5.3. Chlamydia vaccine development
The development of an efficacious vaccine is the greatest potential to prevent infection and the
subsequent development of disease. According to the World Health Organization a vaccine
for the common STI "would have a significant impact on the spread of the disease". An ideal
prophylactic Chlamydial vaccine would target immune responses to each of the two stages of
the Chlamydial life cycle; (1) Antibodies directed against infectious extracellular elementary
bodies preventing cell-adhesion; and (2) T cell mediated immune responses targeting infection
cells during early to mid Chlamydial replication. Both responses require the activation of CD4-
T cells, which have been shown through mouse models to be essential for clearing Chlamydia
in the genital tract [283]. A number of considerations are required when designing vaccines;
choice of antigen and adjuvant, administration route, the potential target of the vaccine (who
to vaccinate?) and the purpose of the vaccine, prophylactic or therapeutic.
Early attempts in the 1950’s and 1960’s to develop a Chlamydial vaccine were based on the
Pasteurian principle of isolate, inactivate and inject [284].However, although this has been a
useful principle in the development of vaccine for veterinary field leading to a commercial
vaccine for feline Chlamydial infections [285] a human whole-cell vaccine has been unsuc‐
cessful. Although crude whole cell vaccine trials in against ocular Trachoma in humans had
observed short-term protection in 70% of vaccinated individuals, the development of strong
pro-inflammatory immune responses to bacterial components led to adverse side effects in
vaccinated individuals. Furthermore, vaccine trials using primates reported the generation of
hypersensitivity leading to increased inflammation and extensive ocular scarring in vaccine
recipients therefore whole Chlamdyia vaccine trials in humans subsequently were abandoned
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[286]. This work suggested that specific antigens within the Chlamydia proteome are associated
with protection while others mediate immunopathology that may be shared between Chla‐
mydial strains. The recent development of genomic and proteomic technology has provided
an unbiased approach to antigen discovery for the generation of a sub-unit Chlamydia vaccine
[287]. Antigen discovery approaches have included; (1) 2D gel elctrophoresis combined with
immunoblotting or radio-immunprecipitation for the discovery of antibody specific antigens
[288-290]; (2) Genome-wide protein expression to discover both antibody and T cell antigens
[291]; (3) Antigen discovery using of T cell clone lines [292] and; (4) Immunoproteomic
approach to identify peptides presented to CD4+ T cells on class II MHC molecules [293].
Sub-unit vaccines provide safer alternatives to whole cell preparations and a number of
Chlamydia antigen candidates have been investigated [294]. A number of antigens have been
used unsuccessfully in animal trials that include cHsp60 and Chlamydial lipopolysaccharide
(cLPS). Chlamydial Hsp60 is an important pathogenicity factor for the development of human
Chlamydial infection-associated disease sequelae [295]. Although Chlamydia specific immun‐
ity is generated, cHsp60 as an antigen was associated with the induction of inflammation
limiting the potential as a vaccine antigen. Chlamydial LPS was a prime antigen candidate due
to its localization to the outer cell membrane. Unfortunately, immunization with LPS does not
induce the production either of post-immunization or of post-infection antibodies and does
not confer protection following live bacterial challenge in primate ocular infection models
[296]. Immunization with surface exposed membrane proteins have proved more successful
in animal models. These include the Chlamydial major outer membrane protein (MOMP) and
the polymorphic membrane protein family (Pmps). The 40kDa MOMP constitutes 50-60% of
the outer membrane of the bacterium [297-299]. To date, Chlamydial MOMP has been the
leading vaccine antigen candidate investigated in animal models, including non-human
primate models. Within the many serovars of the C. trachomatis species a large amount of
primary structural homology is observed, however, antigenic properties of MOMP are related
to the serovar specific surface exposed variable domain (VD) regions. For example, serological
studies have shown cross reactivity between the Chlamydial L2 and D serovars, but the G, H
and I serovars differ significantly [300]. Therefore the use of Chlamydial MOMP from one
serovar results in only serovar-specific immunity and this alone is not sufficient for an effective,
protective, multi-serovar vaccine. Combining multiple MOMP proteins from specific serovars
in a multi sub-unit vaccine may potentially protect against the most common human genital
tract infections. Recently with the aid of immunproteomics Brunham and colleagues identified
the expression of several Pmps which when used in mouse C. muridarum infection model led
to the production of neutralizing antibodies in vitro and partial protective immunity in vivo
[301, 302]. Pmp antigens have also been reported to be immunogenic in human infections [303].
In contrast to EB membrane-bound antigens, Chlamydial secreted proteins have been used as
antigen targets. During intracellular Chlamydia replication, proteins are secreted from the
inclusion body into the host cytosol and may therefore be available for processing and
packaging on MHC molecules, thus specifically inducing T cell immunity. The secreted
proteins known as Inclusion proteins (Inc) and Chlamydial proteasome/protease-like activity
factor (CPAF) have been shown to be potential vaccine targets in mouse models [304, 305].
During Chlamydial infection of humans, both CPAF and Inc antigen specific responses are
Immune Regulation of Chlamydia trachomatis Infections of the Female Genital Tract
http://dx.doi.org/10.5772/57542
197
observed supporting their potential as antigens in a human vaccine [305, 306] [305]. A number
of Chlamydial antigens trialled as vaccine candidates have recently been reviewed by Hafner
et al. [27].
Although sub-unit vaccines provide safer alternatives to the use of live or attenuated organ‐
isms, they are poorly immunogenic. Adjuvants are required to direct the immune response to
a co-administrated antigen. For Chlamydia, a balance of Th2 driven neutralizing antibodies and
Th1 cytokine production characterized by strong IFN-g within the FGT mucosae is required.
A number of adjuvants have been developed for use experimentally in trials for Chlamydial
vaccines. These include live viral vectors [307], immunostimulating complexes such as DDA
and ISCOMs [308, 309, liposomes [310], detergent/surfactant-based adjuvants [311, Lipid
formulations [312,313, Vibrio cholerae ghosts [314, unmethylated 1.7.4.1CPG-ODN bacterial
motifs [308,222] and cytokines [315]. In addition to antigen and adjuvant combinations, the
route of immunization is an important component of vaccination strategies. Historically most
vaccines are delivered through injection that is either sub-cutaneous (S.C) or intra-muscular
(I.M). Although effective in generating strong systemic immunity, the generation of mucosal
immunity has shown to be varied and limited when using systemic immunization routes.
However, these methods have shown in animal models to generate partial protection against
Chlamydia infections. A recent study by Eko et al. (2011) using I.M. vaccination of Chlamydia
antigens expressed by Vibrio Cholerae Ghosts (VVG) has shown to be effective in reducing
the duration of infection in mice; however, sterilizing immunity was not observed in this trial
[316]. Another approach is targeting the mucosal immune system directly with needle free
mucosal routes. Not only are mucosal immunization regimes able to generate immunity and
multiple mucosal surfaces, the needle free nature of delivery has the advantage of being safe
and inexpensive to deliver. Immunization with candidate Chlamydial vaccines via mucosal
routes such as oral [312], intranasal [223,317], intravaginal [318 and transcutaneous
[222,223,313] have shown to target protective immunity in the female reproductive tract; again,
however sterilizing immunity has not yet been achieved using these vaccine approaches.
Over the past 60 years since the first crude whole cell Chlamydial vaccines were investigated,
a number of technologies such as gemomic sequencing have enhanced the forward movement
of the development of a protective Chlamydial vaccine. In light of the continued increased
infection and re-infection rates, even with aggressive screening and treatment programs, the
need for an efficacious Chlamydial vaccine is essential. Mathematical modeling that simulates
transmission of Chlamydia in a heterosexual population has been developed to determine the
impact of an efficacious vaccine regime [319]. The model tracks the infection time course,
disease progression, and dynamic infectiousness of infected individuals and the transmission
to others. This model determined that a fully protective vaccine administered prior to sexual
debut could eradicate Chlamydial epidemics within 20 years. Furthermore, the specific
targeting of women (100% vaccine coverage) would have an increased impact in reducing
epidemiology than vaccination 50% of the male and female population together. However,
currently no vaccine has been shown to generate sterilizing immunity. Modelling reports that
in the absence of a sterilizing vaccine, a Chlamydia vaccine effective for at least 10 years would
provide order to lead to population-level eradication. Furthermore, a non-sterilizing vaccine
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could protect individuals by raising the infectiousness threshold and secondary reduce the
peak load and the duration of the infection in vaccinated individuals. Animal models have
shown that some experimental vaccines, although not producing sterilizing immunity in these
models, may reduce the development of pathology e.g. hydrosalphinx in the murine model.
This suggests that a therapeutic vaccine could potentially be given to women a past or even
current infection to prevent the development of pathology. Although little work has been
undertaken in this area, Carey et al. reported that in the mouse C. muridarum model vaccination
during or after infection reduction in the strength of the immune response was observed. This
work demonstrates that a therapeutic vaccine could be used to limit an uncontrolled host
response leading to immunopathology during re-infection [320]. In light of the fact that there
currently is no vaccine to prevent Chlamydial genital tract infections in women we believe that
a vaccine designed to reduce bacterial burden and prevent disease may be a more rational
target for future research.
6. Summary/conclusions
In this Chapter we have presented current knowledge of immune regulation during infections
of the female genital tract caused by the intracellular bacterial pathogen, Chlamydia trachoma‐
tis. Our review has highlighted the following information regarding Chlamydial infections of
the FGT:
• Tubal infertility and reproductive damage, preeclampsia and preterm births may poten‐
tially occur in many of the 50 million women who are annually infected with Chlamydia
trachomatis
• Gynecological cancer development is also suggested to be linked with Chlamydial genital
tract infections.
• The majority (70-80%) of genital tract infections in women are asymptomatic
• The annual direct medical cost of sexually transmitted diseases (including Chlamydia and
those caused by HIV) has been estimated at $US16.9 billion
• Urogenital isolates of C.trachomatis may also contain a highly conserved 7.5kB non-integra‐
tive plasmid that has a role in the pathobiology of these organisms
• Chlamydia infections of neonates have been reported to be at 18 percent for ophthalmia
neonatorum and 16 percent for pneumonia for infants exposed to C. trachomatis in vaginal
secretions in the birth canal
• The host inflammatory response to C.trachomatis is involved in immunity but also the
pathology that leads to serious morbidities of chronic pelvic pain, EP and tubal infertility
following female genital tract infection
• Disease outcomes are dependent upon the complex interactions between virulence factors
of, and evasion strategies used by, C.trachomatis and host immune responses including
variants in genetic markers associated with infection and inflammation
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• It is becoming increasingly well documented that sex hormones E2 and P4 regulate host
susceptibility, as well as innate and adaptive immune responses to the sexually transmitted
pathogen Chlamydia infecting the mucosal surfaces of the FGT
• In light of the continued increase in infection and re-infection rates even with aggressive
screening and treatment programs, a need for an efficacious vaccine is essential.
• Finally, since there currently is no vaccine to prevent Chlamydial genital tract infections we
consider that a vaccine designed to reduce bacterial burden and prevent disease pathology
may be a rational target for future Chlamydial research.
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